Mazindol

Article about the use of Mazindol in medical treatment

Mazindol is a sympathomimetic amine used primarily as an anorectic agent in the treatment of obesity. It functions as a central nervous system stimulant and is chemically related to amphetamine.

Pharmacology

Mazindol acts as a monoamine reuptake inhibitor, primarily affecting the reuptake of norepinephrine and dopamine. This action increases the levels of these neurotransmitters in the synaptic cleft, leading to increased stimulation of the central nervous system.

Medical Uses

Mazindol is prescribed for short-term management of exogenous obesity. It is typically used in conjunction with a reduced-calorie diet and exercise. The drug is intended for patients with a body mass index (BMI) of 30 or greater, or 27 or greater in the presence of other risk factors such as hypertension, diabetes mellitus, or dyslipidemia.

Side Effects

Common side effects of mazindol include:

• Insomnia
• Dry mouth
• Constipation
• Increased heart rate
• Nervousness

Serious side effects may include:

• Hypertension
• Palpitations
• Psychosis

Contraindications

Mazindol is contraindicated in patients with:

• Cardiovascular disease
• Hyperthyroidism
• Glaucoma
• History of drug abuse

History

Mazindol was first introduced in the 1970s and was marketed under various brand names, including Sanorex and Mazanor. Its use has declined due to the availability of newer weight-loss medications and concerns about its side effects.

Regulation

Mazindol is classified as a Schedule IV controlled substance in the United States, indicating it has a low potential for abuse relative to substances in Schedule III.

Research

Recent studies have explored the potential use of mazindol in treating narcolepsy and attention deficit hyperactivity disorder (ADHD), due to its stimulant properties.

Also see

• Obesity treatment
• Anorectic
• Central nervous system stimulant
• Monoamine reuptake inhibitor

External links

• Drugs.com: Mazindol
• PubMed: Mazindol